Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 2, 2013, Pages 265-276

  Gäbler, Karoline ^a   Rolvering, Catherine ^a   Kaczor, Jakub ^a,b   Eulenfeld, René ^a,c   Méndez, Sergio Álvarez ^a   Berchem, Guy ^d   Palissot, Valérie ^d   Behrmann, Iris ^a   Haan, Claude ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Aurora kinases; CEP701; Jak2V617F; Janus kinases; Kinase inhibitors; MPN

Indexed keywords

AURORA KINASE; CARBAZOLE DERIVATIVE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; LESTAURTINIB; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CFU COUNTING; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROLEUKEMIA; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

AURORA KINASES; BLOTTING, WESTERN; CARBAZOLES; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; HUMANS; JANUS KINASE 2; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84874368903     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12005     Document Type: Article

References (47)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-61.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-8.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352: 1779-90.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7: 387-97.
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005; 280: 22788-92.
6. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22: 14-22.
7. Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med. 2010; 14: 504-27.
8. Haan S, Wuller S, Kaczor J, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009; 28: 3069-80.
9. Garcon L, Rivat C, James C, et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006; 108: 1551-4.
10. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA. 2005; 102: 18962-7.
11. Mercher T, Wernig G, Moore SA, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood. 2006; 108: 2770-9.
12. Roder S, Steimle C, Meinhardt G, et al. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001; 29: 694-702.
13. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356: 459-68.
14. Quintas-Cardama A, Kantarjian H, Cortes J, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011; 10: 127-40.
15. Dolgin E. Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov. 2011; 10: 717-8.
16. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012; 119: 2721-30.
17. Harrison C, Verstovsek S, McMullin MF, et al. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol. 2012; 157: 426-37.
18. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011; 365: 1455-7.
19. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366: 787-98.
20. Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol. 2011; 18: 314-23.
21. Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007; 318: 11-9.
22. Carpenter AE, Jones TR, Lamprecht MR, et al. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006; 7: R100.
23. Kamentsky L, Jones TR, Fraser A, et al. Improved structure, function and compatibility for Cell Profiler: modular high-throughput image analysis software. Bioinformatics. 2011; 27: 1179-80.
24. Quentmeier H, MacLeod RA, Zaborski M, et al. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006; 20: 471-6.
25. Dawson MA, Curry JE, Barber K, et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol. 2010; 150: 46-57.
26. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10: 262-7.
27. Gizatullin F, Yao Y, Kung V, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006; 66: 7668-77.
28. Walz C, Crowley BJ, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006; 281: 18177-83.
29. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002; 22: 874-85.
30. Grandage VL, Everington T, Linch DC, et al. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol. 2006; 135: 303-16.
31. Cameron AJ, Escribano C, Saurin AT, et al. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol. 2009; 16: 624-30.
32. Okuzumi T, Fiedler D, Zhang C, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol. 2009; 5: 484-93.
33. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol. 2010; 400: 413-33.
34. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006; 107: 176-83.
35. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol. 2009; 387: 219-32.
36. Andraos R, Qian Z, Bonenfant D, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012; 2: 512-23.
37. Hall T, Emmons TL, Chrencik JE, et al. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr Purif. 2010; 69: 54-63.
38. Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia. 2008; 22: 1828-40.
39. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol. 2005; 12: 621-37.
40. Kreis S, Munz GA, Haan S, et al. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res. 2007; 5: 1331-41.
41. st edn. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2011.
42. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009; 9: 28-39.
43. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010; 115: 1131-6.
44. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29: 789-96.
45. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010; 115: 5232-40.
46. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009; 114: 2984-92.
47. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leuk Res. 2009; 33: 1581-3.